Skip to main content
Clinical Trials/NCT05015907
NCT05015907
Completed
Not Applicable

Ultrasound-guided Selective Supraclavicular Nerve Block for Postoperative Pain Control in Pediatric Patients Receiving Hickman Catheter, Chemoport or Perm Cath Insertion : a Randomized Controlled Trial

Seoul National University Hospital1 site in 1 country50 target enrollmentOctober 22, 2021

Overview

Phase
Not Applicable
Intervention
Ropivacaine
Conditions
Cancer Pediatric
Sponsor
Seoul National University Hospital
Enrollment
50
Locations
1
Primary Endpoint
Pain score
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This prospective randomized controlled trial aims to investigate the effect of ultrasound-guided selective supraclavicular nerve block on pain control after Hickman catheter, chemoport, or Perm cath insertion in children.

Detailed Description

Pediatric patients undergoing surgical insertion of a Hickman catheter, chemoport, or Permcath are randomly assigned to a test group (Ultrasound-guided selective supraclavicular nerve block with Ropivacaine) and a control group (Nerve block is not performed). Immediately after induction of general anesthesia, in the test group, the supraclavicular nerve block was selectively performed using ultrasound using 0.1mL/kg of 0.5% Ropivacaine (Maximum dose: 5mL), and the nerve block was not completed in the control group. After that, a Hickman catheter, chemoport, or Permcath is surgically inserted in the usual way and allowed to recover from anesthesia. The pain score is evaluated between 10 and 30 minutes of entering the recovery room (1 hour after the procedure) and 1 hour, 3 hours, and 24 hours after leaving the recovery room by another research team who is unaware of the group assignment. In addition, the use of additional analgesic drugs and related side effects were collected before discharge.

Registry
clinicaltrials.gov
Start Date
October 22, 2021
End Date
February 24, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jin-Tae Kim

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Pediatric patients receiving Hickman catheter, chemoport, or Perm cath implantation (3 years ≤, \<18 years)
  • One or more of the parents (or guardians), after hearing and understanding a sufficient explanation about this clinical trial, decides to participate voluntarily and agrees in writing to abide by the precautions
  • In the case of a study subject aged seven years or older, a person who voluntarily decides to participate in this clinical trial and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial

Exclusion Criteria

  • Patients who undergo surgery other than the surgery.
  • Patients with diseases whose sensitivity to pain is different from that of the general public
  • Unstable vital signs (heart rate, blood pressure)
  • General contraindications of Ropivacaine
  • Patients with a history of allergy to opioids
  • Severe renal dysfunction (Creatinine\> 3.0 mg/dl)
  • Severe liver dysfunction (aspartate transaminase \> 120 unit/L, alanine aminotransferase \> 120 unit/L)
  • Peripheral nervous system abnormalities
  • At risk of malignant hyperthermia
  • Other cases that the researcher judges to be inappropriate

Arms & Interventions

Selective supraclavicular nerve block

After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).

Intervention: Ropivacaine

Control

The nerve block is not performed in the control group.

Intervention: Control (without intervention)

Outcomes

Primary Outcomes

Pain score

Time Frame: Pain score measured when communication is possible between 10 and 30 minutes after entering the recovery room.

Numeric rating scale is also evaluated if communication is possible

Secondary Outcomes

  • Hospital stay(No more than one month)
  • Pain score(Pain score for 1 hour, 3 hours, and 24 hours after leaving the recovery room)
  • Whether diaphragmatic palsy(Within 24 hours of the end of surgery)
  • Additional narcotic analgesics administered(Within 24 hours of the end of surgery)
  • Additionally administered non-narcotic analgesics(Within 24 hours of the end of surgery)
  • Side effects related to pain medication(Within 24 hours of the end of surgery)
  • Complications related to ropivacaine use(Within 1 hour after procedure)
  • Check the blockage(When communication is possible between 10 and 30 minutes after entering the recovery room.)

Study Sites (1)

Loading locations...

Similar Trials